In millions, except per share items | Dec-31-20 | Dec-31-19 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| 10-K | 10-K | Source | Source | 20-F |
Revenues | 0.1 | 0.1 | 37.1 | 29.8 | 18.1 |
Revenue growth | 19.4% | | 24.7% | 65.0% | |
Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross profit | 0.1 | 0.1 | 37.1 | 29.8 | 18.1 |
Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
Selling, general and administrative [+] | 36.3 | 5.7 | 41.0 | 33.7 | 3.2 |
Sales and marketing | | | 37.1 | 29.8 | |
General and administrative | 36.3 | 5.7 | 3.9 | 3.9 | 3.2 |
Other selling, general and administrative | | | 37.1 | 29.8 | |
Research and development | 25.3 | 26.7 | | | |
Other operating expenses | | | | | 18.1 |
EBITDA [+] | -60.9 | -31.7 | 4.7 | 4.0 | -2.4 |
EBITDA growth | 92.1% | | 16.6% | -269.2% | |
EBITDA margin | -41124.3% | -25547.6% | 12.7% | 13.6% | -13.2% |
Depreciation | 0.6 | 0.6 | 4.7 | 4.3 | 0.5 |
EBITA | -61.5 | -32.3 | 0.0 | -0.2 | -2.8 |
EBITA margin | -41523.6% | -26038.7% | 0.0% | -0.8% | -15.8% |
Amortization of intangibles | | | 3.9 | 3.7 | 0.3 |
EBIT [+] | -61.5 | -32.3 | -3.9 | -3.9 | -3.2 |
EBIT growth | 90.3% | | -1.8% | 23.5% | |
EBIT margin | -41523.6% | -26038.7% | -10.4% | -13.2% | -17.6% |
Interest income | 2.0 | 0.6 | | | |
Interest income | 2.0 | 0.6 | | | |
Other income (expense), net [+] | 0.2 | -6.4 | 48.9 | 39.3 | 17.9 |
Gain (loss) on foreign currency transactions | 0.2 | -0.8 | | | |
Pre-tax income | -59.2 | -38.1 | 45.1 | 35.4 | 14.7 |
Income taxes | 0.1 | 0.0 | 0.0 | -3.7 | 0.0 |
Tax rate | | | 0.0% | | 0.0% |
Net income | -59.3 | -38.1 | 0.0 | 0.0 | 0.0 |
Net margin | -40098.6% | -30711.3% | 0.0% | 0.0% | 0.0% |
|
Basic EPS [+] | ($0.70) | ($1.51) | | | |
Growth | -53.5% | | | | |
Diluted EPS [+] | ($0.70) | ($1.51) | | | |
Growth | -53.5% | | | | |
|
Shares outstanding (basic) [+] | 84.6 | 25.3 | | | |
Growth | 234.9% | | | | |
Shares outstanding (diluted) [+] | 84.6 | 25.3 | | | |
Growth | 234.9% | | | | |
|
EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |